LianBio
CompanyUnited States
LianBio develops 2 assets, the furthest approved, not sold in the US (infigratinib). Mostly small molecule acting on FGFR1, FGFR4 and fgfr3; based in the United States.
- 2
- Assets
- Furthest stage
- Approved, not sold in the US
- Raised
- $638M
- 5
- Trials
- 67
- Signals
Pipeline
2Inhibits FGFR1, FGFR2 and FGFR3 signaling to suppress tumor growth.
Approved, not sold in the US, Small molecule, FGFR1, FGFR4, achondroplasia (Phase 3), advanced cholangiocarcinoma (Phase 3)
Inhibits cardiac myosin ATPase activity, reducing excessive actin–myosin cross-bridge formation and cardiac contractility.
Approved, Small molecule, MYH7, MYL3, Symptomatic Obstructive Hypertrophic Cardiomyopathy, Cardiomyopathy, Hypertrophic
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms12
- Trials5
- Funding rounds and grants3
- Deals2
- Signals20
- Similar companies6